Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Officially PIII / Phase 3 ready Oncology Company

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson May 26, 2023 6:14am

274 Views

Post# 35465245

Officially PIII / Phase 3 ready Oncology Company

Well, the market generaly reward mightily when a biotech become PIII. We should have a big upside today.

New data on June 3...
By doing so, ONCY will be sustaining SP into 7 trading days and more.
Full valuation to mature in about a month.

With these data, our program is phase 3-ready, and efforts to expeditiously advance to a two-arm registrational study of pelareorep-paclitaxel combination therapy are well underway.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"